Abstract In breast cancer, there is a correlation between tissue factor (TF) expression, angiogenesis and disease progression. TF stimulates tumour angiogenesis, in part, through up-regulation of vascular endothelial growth factor (VEGF). Therefore, this study aimed to establish whether TF stimulates angiogenesis and tumour progression directly and independent of VEGF up-regulation. Initially, the effects of TF and VEGF were assessed on endothelial cell migration (Boyden chamber) and differentiation (tubule formation on Matrigel). Subsequently, MDA-MB-436 breast cancer cells, which produce high levels of both TF and VEGF (western blot analysis), were established in vivo, following which tumours were treated three times per week for 3 weeks with intra-tumoural injections of either anti-VEGF siRNA, anti-TF shRNA, the two treatments combined, or relevant controls. Both VEGF and TF significantly stimulated endothelial cell migration and tubule formation (P \ 0.02). Breast cancer xenografts (MDA-MB-436) treated with TF or VEGF-specific agents demonstrated significant inhibition in tumour growth (VEGFsiRNA 61%; ; P \ 0.005). Microvessel density (MVD), a measure of angiogenesis, was also significantly inhibited in all groups (MVD in control = 29 ± 2.9; TFshRNA = 18 ± 1.1; VEGFsiRNA = 16.7 ± 1.5; both = 12 ± 2.1; P \ 0.004), whereas the proliferative index of the tumours was only reduced in the TFshRNA-treated groups (control = 0.51 ± 0.011; TFshRNA = 0.41 ± 0.014; VEGFsiRNA = 0.49 ± 0.013; both = 0.41 ± 0.004; P \ 0.008). These data suggest that TF has a direct effect on primary breast cancer growth and angiogenesis, and that specific inhibition of the TF-signalling pathway has potential for the treatment of primary breast cancer.
Introduction
Angiogenesis, the outgrowth of new capillaries from an existing vascular bed, and haemostasis, the coagulation cascade leading to clot formation, are amongst the most consistent host responses associated with cancer. These interrelated processes have important implications for cancer therapy as hypercoagulability is exhibited by most cancer patients and contributes to the pathogenesis of tumour growth and metastasis by promoting angiogenesis [1] .
Tissue factor (TF) is a 47 kDa transmembrane glycoprotein that safeguards the vascular integrity of tissues by initiating the coagulation cascade following vessel injury [1] . In normal physiological situations, TF expression is restricted to the tunica adventitia and subendothelial cells, however, during tumourigenesis, expression within vascular endothelial cells is also observed. Indeed, up-regulation of TF protein by cancer cells and associated stromal cells has been well documented in breast cancer and other malignant tumours [2] [3] [4] . TF levels have been correlated with advanced stages of malignancy and metastatic potential in different cancers, including breast [2, 4] , suggesting that TF may play a role in tumour progression, which may be related to the putative role of TF in metastatic disease as TF inhibition reduces both melanoma and breast cancer cell metastasis in vivo [5, 6] .
TF indirectly contributes to tumour angiogenesis via generation of thrombin, which releases pro-angiogenic factors from activated platelets and converts circulating fibrinogen to an insoluble fibrin clot, providing a provisional matrix to facilitate blood vessel infiltration (reviewed by [7] ). TF also up-regulates the pro-angiogenic protein, vascular endothelial growth factor (VEGF) [8] , the most potent known stimulator of angiogenesis, and correlates with both microvessel density (MVD; a surrogate marker of angiogenesis) and VEGF expression in breast and colon cancer [2, 3] .
Despite increasing evidence that TF participates in many tumour-related processes, the precise role is incompletely understood, although evidence suggests that therapeutic targeting of TF may inhibit tumour angiogenesis and hence disease progression. This study demonstrates that TF stimulates angiogenesis independent of VEGF up-regulation and provides evidence for the first time that TF-specific knockdown using shRNA technology significantly reduces primary breast tumour growth in vivo.
Methods

Cells
Adult human dermal microvascular endothelial cells (HuDMEC; Promocell, Heidelberg), were cultured in complete microvascular endothelial cell growth medium (EGM; Promocell), and used for a maximum of five passages. MDA-MB-436, MCF-7 and T47D human breast cancer cell lines (ATCC) were routinely tested for key characteristics (including ER and PR status). MDA-MB-436/MCF-7 and T47D cells were cultured in high glucose RPMI 1640 (GIBCO Ò , Paisley, UK) and DMEM (Invitrogen) medium, respectively, containing 1% L-glutamine, 10% FCS and 1% penicillin-streptomycin. All cells were grown at 37°C in a 100% humidified incubator with a gas phase of 5% CO 2 and routinely screened for Mycoplasma.
Tubule formation assay
The HuDMEC tubule formation assay was performed as previously described [9] using EGM and 1% heat inactivated FCS containing VEGF, TF or both (2-50 ng/ml). Tubule formation was measured as the number of cord-like structures, and the number of branch points seen within an entire well. Each experiment contained three replicate wells for each treatment and was repeated three times.
Migration assay
A 48 well-microchemotaxis chamber (Neuro Probe, Cabin John, MD) was used as previously described [9] with VEGF or TF alone or in combination (2-50 ng/ml) placed in the lower chamber, and serum starved HuDMEC in the top chamber. Migrated cells were then fixed, stained and counted at 940 magnification in three random fields per well in three replicate wells and repeated three times.
Cloning of pFRT-H1 shRNA expression vectors Expression plasmids pFRT-H1T-hTFsh (referred to hereafter as hTFshRNA) and pFRT-H1T-mTFsh (referred to hereafter as non-targeting vector control) were generated by directional oligonucleotide cassette mediated cloning into the BglII/KpnI-linearised expression vector pFRTH1tetO, as previously described [10] . The shRNAs were designed to target previously identified optimal humanspecific [11] and murine-specific [6] TF siRNA target sites.
The following oligonucleotides were used for cloning of the shRNA cassettes:
The oligos were annealed pairwise, phosphorylated and ligated into complementary BglII/KpnI-linearised vector, as previously described [10] . Correct sequence of restrictionpositive transformants was confirmed by sequencing in both directions, using the primers 5 0 -caaggtcgggcaggaagag- Quantitative real time PCR
The mRNA was extracted using the tri-reagent Ò system (Sigma, Dorset, UK), from directly lysed cells, and the concentration and purity of total RNA determined by UV light absorption. cDNA was synthesised from 1 lg total RNA using the Taqman reverse transcriptase reagents (Applied Biosystems, Foster City, CA, USA) and SuperScript Ò II Reverse Transcriptase (Invitrogen). Quantitative real time PCR (qRT-PCR) was performed using PCR Master Mix (Eurogentec Ltd, Hampshire, UK), with predesigned sequence specific Taqman Ò gene probes (Applied Biosystems). Quantitative real time PCR cycling conditions were 2 min at 50°C and then 95°C for 10 min, followed by 40 cycles of 15 s at 95°C, followed by 1 min at 60°C. Quantitative real time PCR was detected by ABIPrism 7900HT Sequence Detection System and data processed using GeneAmp (Applied Biosystems). Target gene expression (VEGF and TF mRNA) was normalised to levels of GAPDH endogenous control.
Protein analysis
Protein extracts were prepared by lysing breast cancer cells with a triple cell lysis buffer [9] . Protein concentrations were determined using the bicinchoninic acid assay. Equal amounts of protein extracts (20 lg) were separated via SDS polyacrylamide gel electrophoresis, electrotransferred to nitrocellulose membranes and exposed to anti-TF (4509; American Diagnostica, Inc., Connecticut, USA; 2 lg/ml) or anti-VEGF (A-20; Santa Cruz Biotechnology, Wiltshire, UK; 5 lg/ml). Immunoreactive bands were detected by enhanced chemiluminescence (Amersham), with b-actin as a loading control (Sigma).
Alternatively, conditioned media was collected from relevant samples and centrifuged before TF and VEGF were measured in duplicate using commercial two-antibody sandwich assays kits (TF: Immubind, American Diagnostica; VEGF: Quantikine, R&D Systems, Abingdon, Oxfordshire, UK). The detection limits of the TF and VEGF assays were 10 and 30 pg/ml, respectively. were grown subcutaneously in athymic nude mice until the tumour reached approximately 100 mm 3 (range = 104-119 mm 3 , mean ± SE = 108.9 ± 3.2). Mice were randomly assigned to treatment groups (6/group) and received intra-tumoural injections, three times per week for 3 weeks, of either antiVEGFsiRNA (6 lg in 20 ll lipofectamine 2000; Invitrogen), or anti-TFshRNA (10 lg in 20 ll lipofectamine LTX; Invitrogen), or the two treatments combined; doses were based on previous studies with siRNA [12] or shRNA [13] . Another group of mice received no treatment (WT), while a non-targeting shRNA vector and a scrambled (nontargeting) siRNA were used as negative controls. Tumour growth was assessed using calipers every 2/3 days. At the end of the study, tumours and control tissues were excised and bisected for immunohistochemical analysis.
Immunohistochemical staining
Tissues were fixed in either 10% neutral-buffered formalin or zinc-based fixative for 48 h, then processed into paraffin wax. Immunohistochemistry was performed using a panel of antibodies to murine platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31; 1:100 using zinc-fixed tissues) (Pharmingen, San Diego, CA, USA), human Ki67 (1:100; Dakocytomation Ltd, Cambridgeshire, UK), VEGF (A-20; 1:150; Santa-Cruz Biotechnology, Inc., Santa Cruz, CA, USA), TF (1:150; R&D Systems) using a standard horse radish peroxidase staining procedure [14] . Negative controls were achieved by omission of the primary antibody and replacement with normal mouse IgG (DAKO), normal goat IgG (DAKO), or normal rabbit IgG (DAKO) at a dilution of 1:100.
Histological analysis
Formalin-fixed tissue sections were stained using Haematoxylin and Eosin, and tumour necrosis was assessed using a Chalkley grid method [15] . Microvessel density (MVD), a surrogate marker of angiogenesis, was assessed by obtaining a Chalkley grid score for five hotspots per section, and the sum of the Chalkley scores for each section was termed the cumulative Chalkley score (CSS) [16] . Ki67 staining was assessed as the percentage of tumour cells showing positive staining for Ki67 antigen by counting a minimum of 1,000 cells per tumour section in a total of four areas of viable tumour per section [17] .
Statistical analysis
Statistical analysis was conducted using SPSS v16 software (Chicago, IL, USA). All data presented are means ± SEM, and representative data from one of three replicate experiments are shown. Statistical analysis was performed using a one-way analysis of variance and either the Dunnet's or Mann-Whitney U post hoc test for nonparametric data. Data were considered statistically significant at P \ 0.05.
Results
Effects of TF on HuDMECs in vitro
Tubule formation
HuDMECs elongated and formed tubules on GF-reduced Matrigel in the absence of exogenous stimuli (due to the residual level of growth factors remaining in this matrix), but this was significantly enhanced with the addition of VEGF (P \ 0.01) or to a lesser extent by TF (P \ 0.02) as assessed by the number of tubules and branch points/well (Table 1, Fig. 1a ). The effects of TF on tubule formation were not attributable to stimulation of VEGF production by HuDMECs as an ELISA showed no change in secreted VEGF levels in response to 2-50 ng/ml TF concentrations (untreated = 31 ± 3.2 pg/ml, TF treated = 28 ± 4.5 pg/ ml). When added in combination there was a non-significant increase in tubule number and no difference in the number of branch points compared to either factor alone (Fig. 1) .
Migration
HuDMECs migrated across the fibronectin-coated filters in the absence of exogenous stimuli; however, this was significantly increased in the presence of VEGF (P \ 0.007) or TF (P \ 0.001) ( Table 2) . Moreover, VEGF-stimulated migration to a significantly greater extent than TF (P \ 0.01) and the combination of both factors enhanced migration more than either factor alone, although this failed to reach significance (Fig. 2) .
Effect of p-FRT-H1-TFShRNA on TF/VEGF expression
In order to identify a breast cancer cell line that expressed both TF and VEGF for subsequent study, qRT-PCR and western blot analysis were used to determine basal TF and VEGF gene and protein expression in MDA-MB-436, MCF-7 and T47D breast cancer cell lines. VEGF mRNA was detected in all cell lines examined (Fig. 3a) . In contrast, only MDA-MB-436 cells expressed TF mRNA (higher than VEGF mRNA levels), with negligible TF mRNA detected in either MCF-7 or T47D cells. Western blot analysis was consistent with the gene expression data, showing VEGF expressed by all cell lines, but only detectable levels of TF expressed in MDA-MB-436 cells (Fig. 3b) .
The effects of TF knockdown on TF/VEGF gene and protein expression in MDA-MB-436 cells following transfection with a TF-specific shRNA vector were then determined. Transfection with hTFshRNA significantly decreased both TF mRNA (77 ± 3.3%; P \ 0.001) and protein release (80.3 ± 3.7%; P \ 0.003) (Fig. 3c, d ), whereas VEGF gene expression was unaffected by TF knockdown. Furthermore, there was no difference in VEGF/TF mRNA and protein expression between cells in all control conditions. TF knockdown in MDA-MB-436 cells had no significant effect on proliferation or cell viability assessed using a Vi-cell counter over 4 days (data not shown). Essentially, similar results were obtained using an alternative TF expressing breast cancer cell line, MDA-MB-231, showing *75% knockdown in expression.
Intra-tumoural injections of anti-TFshRNA and anti-VEGFsiRNA inhibit tumour growth in vivo
Direct intra-tumoural injections of anti-TFshRNA or antiVEGFsiRNA alone and in combination, were performed on established MDA-MB-436 tumours to determine whether TF expression plays a key role in primary breast tumour growth and angiogenesis that is functionally distinct from the role in VEGF production (Fig. 4) . Importantly, the nontargeting vector and scrambled siRNA control treatments had no significant effect on final tumour volume compared to the untreated group (367.2 ± 35.9, 352.1 ± 23.1 and 400.4 ± 32.7 mm 3 , respectively, at day 21). In contrast, the TF or VEGF-specific treatments all significantly (P \ 0.005) inhibited tumour growth; treatment with Fig. 1 Tubule formation in response to VEGF and TF. a The number of tubes and b the number of branch points formed in response to VEGF, TF or both at 10 or 20 ng/ml. * P \ 0.01 with respect to relevant control group. c Representative photographs in response to (I) control, (II) 10 ng/ml VEGF, (III) 10 ng/ml TF, and (IV) 10 ng/ml VEGF ? 10 ng/ml TF . Interestingly, the tumour growth inhibition induced by TFshRNA alone or in combination with VEGFsiRNA was significantly greater than treatment with VEGFsiRNA alone (P = 0.018 and P = 0.016, respectively; Fig. 4 ).
Histological analysis of tumours
Histological analysis of control tumour tissue revealed the presence of a central area of necrosis surrounded by a viable rim of tumour cells, which was unchanged by any of the treatment regimes (data not shown). In order to determine whether the reduced volume of both TFshRNA and VEGFsiRNA treated tumours was due to an effect on the tumour vasculature, endothelial cells were identified using CD31 staining (Fig. 5a) . MVD in the viable rim of tumour cells was significantly reduced compared to relevant controls in VEGFsiRNA (P = 0.002), TFshRNA (P = 0.002) and combined (P = 0.004) treatment groups (Fig. 5a) . In order to determine whether the reduced tumour volume was also due to an effect on tumour cell proliferation, the proliferation index was calculated on Ki67 stained sections [17] . In contrast to MVD, only TFshRNA treatment had a significant effect on proliferation index (control: 0.51 ± 0.01 vs TFshRNA: 0.41 ± 0.02; P = 0.008, Fig. 5b) . VEGF staining revealed a relatively homogenous pattern throughout the cytoplasm of tumour cells, with the intensity of staining reduced, but not completely absent in the VEGFsiRNA and combined treated tumours only 
Discussion
Elevated TF expression in breast cancer has been associated with disease progression, poor survival, increased VEGF expression and angiogenesis [2, 4] . VEGF is known to up-regulate the expression of TF in cancer cells and associated endothelial cells, potentially creating a feedback loop whereby TF in turn up-regulates VEGF expression [1] . It has therefore been proposed that inhibition of TF in breast cancer may result in reduced angiogenesis due to down-regulation of VEGF expression. The data presented here, however, provide evidence that TF has the ability to modulate angiogenic mechanisms in vitro in the absence of VEGF up-regulation. Moreover, we demonstrate for the first time that direct intra-tumoural injections of TFshRNA prevent the growth of established primary breast cancer xenografts in vivo by inhibiting both tumour cell proliferation and angiogenesis. It has been well documented that VEGF stimulates angiogenic activities in endothelial cells (reviewed in [18] ), and our data is consistent with other studies showing a dose-dependent increase in HuDMEC migration and tubule formation in vitro. TF also stimulates HuDMEC migration and tubule formation/differentiation, although to a lesser extent, and appears not to be dose dependent or resulting from VEGF up-regulation. This is in agreement with studies demonstrating that soluble TF promotes EC migration and tubule formation [19] and that an alternatively spliced form of TF induces tubule formation independently of VEGF or PAR signalling [20] . In vitro assays from the current study were carried out in the absence of activated factor VII (FVIIa), by using low levels of heat inactivated serum, and data indicate a direct role for TF signalling in EC migration and tubule formation, although the precise mechanisms mediating this response are as yet undetermined. Interestingly, there was only a small additional increase in tubule formation or migration in the presence of both TF and VEGF, compared to VEGF alone, suggesting that VEGF, the most potent angiogenic factor identified to date [8] , is likely to be saturating the In breast cancer, TF is associated with metastatic potential and poor prognosis [4] in addition to playing a role in angiogenesis [2] . The current study demonstrates that TF is highly expressed in metastatic breast carcinoma cells (MDA-MB-436), in contrast to non-metastatic breast carcinoma cells (MCF-7, T47D), although MCF-7 expresses TF under hypoxic conditions (data not shown; [21] ). These observations are in agreement with previous studies, reporting elevated TF expression in metastatic cell lines compared to non-metastatic cell lines of the same tissue origin [22] [23] [24] . Following TF expression knockdown of *80% in the MDA-MB-436 cell line, there was no effect on VEGF expression, suggesting that TF is not involved in regulating VEGF expression in this cell line. Furthermore, TF knockdown had no effect on cell proliferation or viability in vitro over a time course of 4 days, in agreement with other studies using a similar mouse specific construct in B16 melanoma cells [6] .
As previous studies had investigated the effects of murine-specific TF shRNA on metastasis [6] , we used a model of established primary MDA-MB-436 subcutaneous tumours treated with intra-tumoural injections of TFshRNA or VEGFsiRNA alone and in combination, to achieve direct homology-dependent post-transcriptional gene silencing, with subsequent knockdown of protein translation. Our data show that VEGF inhibition significantly reduces primary breast tumour growth and angiogenesis (measured by MVD), in agreement with results from relevant mouse xenograft studies [12, 25, 26] . Interestingly, treatments with TFshRNA (either alone or in combination with VEGFsiRNA) were more potent in reducing primary tumour growth than VEGFsiRNA treatment alone. However, shRNA requires cellular transcription in the nucleus, further processing, then transport to the cytoplasm before being incorporated into the RNA-interfering silencing complex, therefore data generated from administration of siRNA and shRNA are not directly comparable. What is interesting is that addition of TFshRNA to VEGFsiRNA significantly increases tumour inhibition compared to VEGFsiRNA alone. Moreover, these data suggest that TF has a direct role in promoting primary tumour growth that is functionally distinct from the role in VEGF production. This is in agreement with previous in vivo studies using stable TF knockdown in colorectal cancer cells grown in Matrigel plugs which showed a reduction in angiogenesis, but only minimal effects on VEGF expression [27] . Although other groups have previously shown that inhibition of TF signalling suppresses hypoxia-induced retinal angiogenesis [28] and breast tumour growth in vivo [5, 29] , this is the first study to evaluate TF inhibition alone and in combination with VEGF inhibition, in established primary breast tumours.
Our in vivo data show that both treatments (TF and VEGF knockdown) inhibit angiogenesis, but only tumours treated with TFshRNA showed a significantly reduced tumour proliferative index, suggesting that TF knockdown in breast tumour cells reduces proliferation in vivo, in addition to inhibiting angiogenesis. These data therefore indicate that down-regulation of VEGF expression can inhibit co-option or invasion of murine ECs, whilst the anti-tumour response to TF knockdown may also, in part, be attributed to direct effects on breast tumour cell proliferation. These data are consistent with observations from previous studies on gene expression in a human melanoma cell line demonstrating down-regulation of genes involved in cell growth, invasion and metastasis and an up-regulation of genes involved in apoptosis, and reduced cell proliferation following TF knockdown using TFshRNA [11] . Differences between in vitro and in vivo proliferation responses are likely to be attributable to other tumour microenvironmental factors in vivo. Although breast cancer cell lines express PAR-2, which becomes activated in the presence of TF-FVIIa stimulating signalling pathways potentially resulting in proliferation [30] , data relating to the direct effects of TF on proliferation are contradictory [27, 31, 32] .
Whilst this study using TFshRNA, and others using inactivating peptides and antibodies [5, 29] , show a definite effect of TF inhibition on primary tumour growth in vivo, clinical applications of systemic anti-TF therapy are likely to be associated with significant risks, due to the essential role of the haemostatic pathway. Indeed, a phase I clinical trial using a monoclonal antibody against TF showed an increase in the frequency of haemorrhagic events such as oral mucosal bleeding, cutaneous bleeding and spontaneous tongue haematomas in a dose-dependent manner [33] . These side effects may be circumvented by the development of specific inhibitors that suppress TF-FVIIa signalling in pathological angiogenesis, but not in TF-FVIIa coagulant function [29] , although such an approach requires full evaluation. Alternative approaches such as using atellocollagen or nanoparticles to specifically target shRNA/siRNAs to tumours following systemic administration, are also beginning to show some efficacy in vivo [34] [35] [36] . These methods require further validation, but may prove effective for tumour-specific targeting of TF with shRNA or siRNA via systemic delivery, thereby circumventing the haemostatic side effects associated with systemic anti-TF treatment.
In conclusion, these data suggest for the first time that modulation of TF has a direct effect on established primary breast cancer growth and angiogenesis that is distinct from the role in VEGF production. Therefore, similar to a potential use suggested for gliomas [32] , specific inhibition of the TF-signalling pathway with shRNA or siRNA represents a powerful tool for inhibiting cancer cell proliferation and angiogenesis in vivo with potential therapeutic utility for the effective treatment of primary breast cancers using targeted therapy. Further work is now required to investigate the effects of TF knockdown in models relevant to breast cancer metastasis.
